Did You Know?

Did you know that the FDA is currently taking comments on the recently issued PGx Draft Guidance for Pharmaceutical Manufacturers?

Mar 22, 2011 | Free Downloads | email | Print

Share This Article

Until April 19, 2011 FDA is taking comments regarding the recently issued PGx Draft Guidance. The guidance documentation was written to provide recommendations to drug manufacturers regarding how genomic information can be used during the drug development process. According to GenomeWeb News the draft's primary purpose is "...helping drug developers evaluate how human genomic variations can affect the way drugs function in different people and how they can cause varying clinical responses."1 Also according to GenomeWeb News, "The specific goals of this document...is to provide advice related to general principles of study design, data collection, and data analysis when using pharmacogenomic approaches in pharmaceutical development."2

Learn More

Learn more about the new guidance:
PGx Guidance Document.

1-2 http://www.genomeweb.com/dxpgx/fda-issues-pgx-draft-guidance

Share This Article

Watch Related Videos

Download Free Resources
White Paper: FDA Experts Offer Top Tips to Optimize Your eCTD Submission
White Paper: Contracting Organizations and the Need for Written Transfer Obligations and Quality Agreements
White Paper: Drug and Device Accountability Act of 2008: How Execs can Avoid Jail Time
White Paper: Getting Less For Your Money Isn't Always A Bad Thing